Advanced ALK-positive NSCLC Market Outlook

Thelansis’s “Advanced ALK-positive NSCLC Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced ALK-positive NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced ALK-positive NSCLC Overview

Advanced ALK-positive non-small cell lung cancer (ALK-positive NSCLC) is a molecularly defined lung adenocarcinoma subtype driven by oncogenic EML4-ALK fusions, constitutively activating RAS-MAPK, PI3K-AKT, and JAK-STAT proliferative signalling. Representing approximately 3-5% of NSCLC, it predominantly affects younger never-smoker patients, frequently presenting with advanced disease and central nervous system metastases. ALK rearrangement detection via fluorescence in situ hybridisation, immunohistochemistry, or next-generation sequencing is mandatory at diagnosis. Lorlatinib, a third-generation ALK inhibitor with exceptional CNS penetration and broad resistance mutation coverage, is now the undisputed frontline standard of care, supported by the historic CROWN trial 7-year follow-up presented at ASCO 2026 demonstrating an unprecedented progression-free survival rate of 55% at seven years with median PFS still unreached, fundamentally redefining the ceiling for targeted monotherapy in solid tumours. Alectinib and brigatinib retain relevance as frontline alternatives in lorlatinib-ineligible patients. Resistance to lorlatinib driven by complex compound mutations including G1202R plus L1196M represents the critical emerging challenge; neladalkib, a fourth-generation TRK-sparing ALK inhibitor specifically engineered to overcome lorlatinib resistance, has an NDA submitted to the FDA as of early 2026 and currently serves as the standard-of-care clinical bridge for lorlatinib-refractory disease. Chemotherapy retains limited salvage utility. Prognosis is markedly favourable; multidisciplinary molecular tumour board evaluation, CNS surveillance, and patient-centred long-term monitoring are integral to optimising outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)